ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Allurion Technologies's annualizedNet Income for the quarter that ended in Mar. 2026 was $-24.38 Mil.
Allurion Technologies's average Total Assets over the quarter that ended in Mar. 2026 was $14.88 Mil. Therefore, Allurion Technologies's annualized ROA % for the quarter that ended in Mar. 2026 was -163.81%.
The historical rank and industry rank for Allurion Technologies's ROA % or its related term are showing as below:
ALURD'
s ROA % Range Over the Past 10 Years
Min: -145.64 Med: -83.21 Max: -13.77
Current: -145.64
During the past 5 years, Allurion Technologies's highest ROA % was -13.77%. The lowest was -145.64%. And the median was -83.21%.
ALURD's ROA % is ranked worse than 94.52% of 857
companies
in the Medical Devices & Instruments industry
Industry Median: 0.59
vs ALURD: -145.64
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Allurion Technologies's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Allurion Technologies ROA % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Allurion Technologies's ROA % distribution charts can be found below:
* The bar in red indicates where Allurion Technologies's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
ROA % is displayed in the 30-year financial page.
Allurion Technologies (ALURD) has a ROA % of -163.81% as of Mar. 2026. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Allurion Technologies and its competitors. According to the industry distribution chart, Allurion Technologies ranks #810 out of 857 companies in the Medical Devices & Instruments industry, placing it in the top 94.5%.
Is Allurion Technologies' ROA % too high?
Allurion Technologies' current ROA % is -163.81%. Based on the distribution chart, Allurion Technologies ranks #810 out of 857 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Allurion Technologies has a GF Score™ of 16/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Allurion Technologies' ROA % compare to ALRTF and VVOS?
According to the Medical Devices & Instruments industry distribution chart, Allurion Technologies ranks #810 out of 857 companies for ROA %. This places Allurion Technologies in the lower half of its industry. The industry median ROA % is 0.59. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Medical Devices & Instruments company?
The median ROA % among Medical Devices & Instruments companies is 0.59, based on 857 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Allurion Technologies and its competitors. For the Medical Devices & Instruments industry, the median ROA % is 0.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Allurion Technologies's current ROA % is -163.81%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Allurion Technologies stock overvalued right now?
Based on GuruFocus' analysis, Allurion Technologies (ALURD) is currently considered Possible Value Trap. The stock's GF Value™ is $10.66, compared to a current price of $5.91 — trading 44.6% below its estimated fair value. The current ROA % is -163.81%. Allurion Technologies' overall GF Score™ is 16/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Allurion Technologies (ALURD), the current ROA % is -163.81% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Allurion Technologies (ALURD) Overvalued in 2026?
Based on GuruFocus' analysis, Allurion Technologies stock appears to be undervalued.
The current stock price of $5.91 is trading 44.6% below its estimated GF Value™ of $10.66.
GuruFocus considers Allurion Technologies to be Possible Value Trap.
Key valuation signals for ALURD:
ROA %: -163.81%
GF Value™: $10.66 vs. price of $5.91 (44.6% below fair value)
No single metric tells the full story. See the ALURD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Allurion Technologies Inc is a medical device company that focuses on creating a weight loss platform to treat overweight patients. Its platform, the Allurion Program, features the world's first and only swallowable, procedure-less intragastric balloon for weight loss and offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion VCS. Its proprietary intragastric balloon, the Allurion Balloon, is in the form of a swallowed capsule that is administered to patients under the guidance of a healthcare provider without surgery, endoscopy, or anesthesia.
16GF Score
Get the complete analysis for ALURD
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ALURD has been successfully added to your 
